Sandoz ‘Bucks Trend’ With Completion Of GSK Cephalosporins Deal
CEO Richard Saynor Insists On The Importance Of Investing In Antibiotics
Sandoz has completed the acquisition of GSK’s cephalosporin antibiotics business which includes the Zinnat, Zinacef and Fortum brands in more than 100 markets. Commenting as the deal closed, Sandoz CEO Richard Saynor emphasized the importance of investing in antibiotics.
You may also be interested in...
Acquiring Astral SteriTech will open up significant new capabilities in sterile injectables for Centrient while also offering an opportunity to expand the reach of the Indian firm’s products through Centrient’s infrastructure, CEO Rex Clements tells Generics Bulletin in an exclusive interview.
Sandoz has shed some light on how it intends to invest €150m into its European antibiotics manufacturing network, while announcing the closure of a plant in Spain to remain “cost-competitive on the global market.”
Sandoz has announced joint plans with the Austrian government to invest over €150m in antibiotics manufacturing.